Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- 1 March 2013
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (5), 1212-1216
- https://doi.org/10.1016/j.bmcl.2013.01.019
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092MedChemComm, 2011
- The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinaseBioorganic & Medicinal Chemistry Letters, 2009
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promisesCurrent Opinion in Pharmacology, 2008
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLoS Medicine, 2008
- Growing roles for the mTOR pathwayCurrent Opinion in Cell Biology, 2005
- mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4EMolecular and Cellular Biology, 2004
- Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovascular Research, 2003
- Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4EGenes & Development, 2002
- Phosphatidylinositol 3-kinase related kinasesCurrent Opinion in Immunology, 1996
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994